Peggy Scherle, Chief Scientific Officer at Prelude Therapeutics Inc (PRLD), sold 7,716 shares at $39.57 ($296K) on 2021-04-08, disclosed to the SEC on 2021-04-15.
Open-market sale of $296k PRLD by Chief Scientific Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $36.97 | 1,417 | $52K | 17.7% |
| 2 | $36.97 | 1,417 | $52K | 17.7% |
| 3 | $37.72 | 875 | $33K | 11.2% |
| 4 | $38.97 | 669 | $26K | 8.8% |
| 5 | $39.57 | 1,669 | $66K | 22.3% |
| 6 | $39.57 | 1,669 |
| $66K |
| 22.3% |
| Total | $38.35 avg | 7,716 | $296K | 100% |
| Filing → |
| PRLD | SELL | 2021-07-29 | $709K | — | Filing → |
| PRLD | SELL | 2021-05-11 | $808K | — | Filing → |
| PRLD | SELL | 2021-04-09 | $1.2M | — | Filing → |